Big Pharma makes ‘creative effort’ to fold Chinese assets into pipelines

▤ Summary

Big Pharma is taking a more collaborative approach to China by structuring broader pipeline partnerships with Chinese biotech companies. Pfizer and Bristol Myers Squibb each committed billions of dollars to deals that combine assets from both sides rather than simply licensing single programs. The partnerships spread risk, speed up early development, and create more shared commercial rights across regions. These moves suggest a more flexible model for building drug pipelines and advancing candidates in oncology, immunology, and other therapeutic areas.

▦ Linked Companies